buy

Esperion Therapeutis.Inc. buy HC Wainwright

Esperion Therapeutis.Inc.

Start price

€2.49

/ 50%

Target price

25.03.25

Performance (%)

Price

Summary

This prediction is currently active. The price of Esperion Therapeutis.Inc. has decreased since the start of the prediction. Compared to the start price this results in a performance of . This prediction currently runs until 25.03.25. The prediction end date can be changed by HC_Wainwright at any time. HC_Wainwright has 50% into this prediction

Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.

Feedback

Performance without dividends (%)

Name	1w	1m
Esperion Therapeutis.Inc.
iShares Core DAX®
iShares Nasdaq 100
iShares Nikkei 225®
iShares S&P 500

Comments by HC_Wainwright for this prediction

In the thread Esperion Therapeutis.Inc. diskutieren

Prediction Buy

Perf. (%)

Target price 14.763

Change

Ends at

Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.

Ratings data for ESPR provided by MarketBeat

HC Wainwright